4.7 Article

Association between Body Composition and Frailty among Prevalent Hemodialysis Patients: A US Renal Data System Special Study

Journal

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 25, Issue 2, Pages 381-389

Publisher

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2013040431

Keywords

-

Funding

  1. National Institutes of Health [N01-DK-0005, N01-DK-2450]

Ask authors/readers for more resources

Studies of frailty among patients on hemodialysis have relied on definitions that substitute self-reported functioning for measures of physical performance and omit weight loss or substitute alternate criteria. We examined the association between body composition and a definition of frailty that includes measured physical performance and weight loss in a cross-sectional analysis of 638 adult patients receiving maintenance hemodialysis at 14 centers. Frailty was defined as having three of following characteristics: weight loss, weakness, exhaustion, low physical activity, and slow gait speed. We performed logistic regression with body mass index (BMI) and bioelectrical impedance spectroscopy (BIS)-derived estimates of intracellular water (ICW), fat mass, and extracellular water (ECW) as the main predictors, and age, sex, race, and comorbidity as covariates. Overall, 30% of participants were frail. Older age (odds ratio [OR], 1.31 per 10 years; 95% confidence interval [95% CI], 1.14 to 1.50), diabetes (OR, 1.65; 95% CI, 1.13 to 2.40), higher fat mass (OR, 1.18; 95% CI, 1.02 to 1.37), and higher ECW(OR, 1.33; 95% CI, 1.20 to 1.47) associated with higher odds of frailty. Higher ICW associated with lower odds of frailty (OR, 0.80 per kg; 95% CI, 0.73 to 0.87). The addition of BMI data did not change the area under the receiver operating characteristics curve (AUC; AUC=0.66 versus 0.66; P=0.71), but the addition of BIS data did change the AUC (AUC=0.72; P < 0.001). Thus, individual components of body composition but not BMI associate strongly with frailty in this cohort of patients receiving hemodialysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

Cardiovascular Drug Use After Acute Kidney Injury Among Hospitalized Patients With a History of Myocardial Infarction

Alejandro Y. Meraz-Munoz, Nivethika Jeyakumar, Bin Luo, William Beaubien-Souligny, Rahul Chanchlani, Edward G. Clark, Ziv Harel, Abhijat Kitchlu, Javier A. Neyra, Michael Zappitelli, Glenn M. Chertow, Amit X. Garg, Ron Wald, Samuel A. Silver

Summary: Patients with a history of MI who survived AKI were less likely to receive prescriptions for cardiovascular drugs within 1 year of hospital discharge. This association was most pronounced in patients with stages 2 and 3 AKI.

KIDNEY INTERNATIONAL REPORTS (2023)

Article Endocrinology & Metabolism

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Jelle M. Beernink, Frederik Persson, Niels Jongs, Gozewijn D. Laverman, Glenn M. Chertow, John J. V. McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: This study aimed to determine whether the benefits of dapagliflozin varied by background glucose-lowering therapy (GLT) in patients with type 2 diabetes and chronic kidney disease (CKD). The results demonstrated consistent effects of dapagliflozin on both primary and secondary endpoints across different baseline GLT classes or combinations. Therefore, dapagliflozin has significant clinical implications in reducing kidney and cardiovascular events.

DIABETES CARE (2023)

Article Medicine, General & Internal

Population-Wide Screening for Chronic Kidney Disease A Cost-Effectiveness Analysis

Marika M. Cusick, Rebecca L. Tisdale, Glenn M. Chertow, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert

Summary: Adding SGLT2 inhibitors to CKD screening can be cost-effective, with a one-time screening at age 55 having an ICER of $86,300 per QALY gained, reducing the incidence of kidney failure. Screening every 10 years from age 35 to 75 costs less than $100,000 per QALY gained.

ANNALS OF INTERNAL MEDICINE (2023)

Article Oncology

Groundwater constituents and the incidence of kidney cancer

Simon John Christoph Soerensen, Maria E. Montez-Rath, Iona Cheng, Scarlett Lin Gomez, Debora L. Oh, Christian Jackson, Jinhui Li, David Rehkopf, Glenn M. Chertow, Marvin E. Langston, Calyani Ganesan, Alan C. Pao, Benjamin I. Chung, John T. Leppert

Summary: This study evaluated the association between groundwater exposures and kidney cancer incidence and identified several groundwater constituents associated with kidney cancer. Public health efforts to reduce the burden of kidney cancer should consider groundwater constituents as environmental exposures that may be associated with the incidence of kidney cancer.

CANCER (2023)

Article Urology & Nephrology

Feasibility and Acceptability of SARS-CoV-2 Screening among Patients Receiving Hemodialysis A Pilot Study

Shuchi Anand, Maria Montez-Rath, Meri Varkila, Xue Yu, Martha Block, Stephanie Brillhart, Amanda Leppink, Patti Hunsader, Douglas K. Owens, Glenn M. Chertow, Julie Parsonnet, Geoffrey A. Block

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Kidney Stone Events after Kidney Transplant in the United States

Calyani Ganesan, Malorie Holmes, Sai Liu, Maria Montez-Rath, Simon Conti, Timothy C. C. Chang, Colin R. Lenihan, Xingxing S. S. Cheng, Glenn M. Chertow, John T. Leppert, Alan C. C. Pao

Summary: Background: Kidney stone disease is common and can lead to complications in kidney transplant recipients. This study found that approximately 2% of kidney transplant recipients were diagnosed with a kidney stone in the first 3 years after transplantation. Risk factors for kidney stone events included a history of kidney stones and longer dialysis vintage.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Cardiac & Cardiovascular Systems

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial

Glenn M. Chertow, Ricardo Correa-Rotter, Priya Vart, Niels Jongs, John J. V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: In the DAPA-CKD trial, dapagliflozin was found to reduce the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria. The treatment effect of dapagliflozin was consistent regardless of baseline cardiovascular medication use.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Review Physiology

The potential roles of galectin-3 in AKI and CKD

Fengyun Wang, Lixin Zhou, Amity Eliaz, Chang Hu, Xinhua Qiang, Li Ke, Glenn Chertow, Isaac Eliaz, Zhiyong Peng

Summary: Acute kidney injury (AKI) and chronic kidney disease (CKD) are associated with high morbidity and mortality. Galectin-3 (Gal3), a protein with proinflammatory and profibrotic properties, has been implicated in the development and progression of both AKI and CKD. Elevated Gal3 levels in the serum of AKI and CKD patients and its association with CKD progression have been observed. Gal3 is also associated with AKI incidence in critically ill patients, and blocking Gal3 has shown promising results in reducing AKI incidence and mortality in animal models.

FRONTIERS IN PHYSIOLOGY (2023)

Letter Medicine, General & Internal

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

Priya Vart, Niels Jongs, David C. Wheeler, Hiddo J. L. Heerspink, Anna Maria Langkilde, Glenn M. Chertow

JAMA NETWORK OPEN (2023)

Letter Medicine, General & Internal

Disparities in the Timing of Preoperative Hemodialysis Among Patients With End-Stage Kidney Disease

Vikram Fielding-Singh, Matthew W. Vanneman, Arden M. Morris, Glenn M. Chertow, Eugene Lin

Summary: This cohort study examines the relationship between patient characteristics and the time interval between hemodialysis and surgery in end-stage kidney disease patients.

JAMA NETWORK OPEN (2023)

Meeting Abstract Transplantation

REASONS FOR DIALYSIS INITIATION AND SAFETY OF DAPAGLIFLOZIN AMONG DIALYSIS PARTICIPANTS: NEW INSIGHTS FROMDAPA-CKD

Hiddo Lambers Heerspink, David C. Wheeler, Niels Jong, Ricardo Correa-Rotter, Peter Rossing, Ronald Gansevoort, John Mcmurray, Anna Maria Langkilde, Robert Toto, Glenn Chertow

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Meeting Abstract Transplantation

APOL1 GENOTYPING AND PROTEINURIC KIDNEY DISEASE IN EUROPE

Bertrand Knebelmann, Kate Bramham, Kieran Mccafferty, Mohamad Zaidan, Pablo Antonio Urena Torres, Vincent Audard, Jean Jacques Boffa, Thomas Powell, Nauman Shahid, Diego Echeverri, Christopher Provenzano, John Bauman, Aurelia Zamauskaite, Irisz Delestre-Levai, Yuan Yang, Silva Krause, Anna Carolina Ferreira, Ogo Egbuna, Glenn Chertow

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Meeting Abstract Transplantation

EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH CKD ACROSS THE SPECTRUM OF AGE AND BY SEX

Margaret Yu, Priya Vart, Hiddo Lambers Heerspink, Niels Jong, Ricardo Correa-Rotter, John Mcmurray, Peter Rossing, Anna Maria Langkilde, Robert Toto, David C. Wheeler, Glenn Chertow

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Meeting Abstract Transplantation

AMBIENT HEAT EXPOSURE AND ESTIMATED GLOMERULAR FILTRATION RATE TRAJECTORY: A POST-HOC ANALYSIS OF THE DAPA-CKD TRIAL

Zhiyan Zhang, Hiddo Lambers Ileerspink, Glenn Chertow, Ricardo Correa-Rotter, Antonio Gasparrini, Niels Jong, Anna Maria Langkilde, Malcolm Mistry, John Mcmurray, Peter Rossing, Robert Toto, Priya Vart, Dorothea Misch, David C. Wheeler, Ben Caplin

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Meeting Abstract Medicine, Research & Experimental

Class I and II Human Leukocyte Antigen Serotypes Associated with End-Stage Kidney Disease due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease

Halimat Afolabi, Bing Zhang, Michelle O'Shaughnessy, Glenn Chertow, Richard Lafayette, Vivek Charu

LABORATORY INVESTIGATION (2023)

No Data Available